AIDS dementia

Medical Clinics of North America

Volumn 86, Issue 3, 2002, Pages 537-550

  Clifford, David B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AIDS RELATED COMPLEX; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036322729     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00005-6     Document Type: Review

References (67)

1. AIDS - The first 20 years
2. Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients
3. The AIDS dementia complex: I. Clinical features
4. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection
5. Viral kinetics: Implications for treatment
6. HIV-1-related neurological disease incidence changes in the era of highly active antiretroviral therapy
7. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
8. Dementia in AIDS patients: Incidence and risk factors
9. Effect of chronic substance abuse on neuropsychological performance in intravenous drug users with a high prevalence of HIV-1 seropositivity
10. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
11. Review article: The neuropathology of AIDS-UCLA experience and review
12. The neuropathology of adult HIV infection
13. The neuropathology of human immunodeficiency virus infection
14. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder
15. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorder
16. AIDS does not alter the total number of neurons in the hippocampal formation but induces cell atrophy: A stereological study
17. Neocortical damage during HIV infection
18. Neuronal loss in the frontal cortex in HIV infection
19. Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome
20. Preferential loss of large neocortical neurons during HIV infection: A study of the size distribution of neocortical neurons in the human brain
21. Varicella-zoster virus encephalitis in acquired immunodeficiency syndrome: Report of four cases
22. Pathways to neuronal injury and apoptosis in HIV-associated dementia
23. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia
24. The metabolic pathology of the AIDS dementia complex
25. Reduced basal ganglia volume in HIV-1-associated dementia: Results from quantitative neuroimaging
26. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry
27. HIV in the brain-RNA levels and patterns of zidovudine resistance
28. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide
29. Human immunodeficiency virus type 1 Tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity
30. Neurobiological aspects of human immunodeficiency virus infection: Neurotoxic mechanisms
31. Molecular pathway involved in HIV-1-induced CNS pathology: Role of viral regulatory protein, Tat
32. Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands
33. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia
34. 2-microglobulin in patients with AIDS dementia complex: An expanded series including response to zidovudine treatment
35. 2-microglobulin in HIV-1 dementia
36. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection
37. Perspectives series: Cytokines and the brain
38. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: Relationship to clinical and neurological status
39. Unique monocyte subset in patients with AIDS dementia
40. AIDS: HIV infection and dementia
41. White matter abnormalities in HIV-1 infection: A diffusion tensor imaging study
42. Cytomegalovirus encephalitis
43. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome
44. Elevated levels of soluble fas and fas ligand in cerebrospinal fluid of patients with AIDS dementia complex
45. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex
46. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia
47. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients
48. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study
49. Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex
50. Abacavir-lamivudine-zidovudine vs indinavirlamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
51. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
52. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
53. Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system
54. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents
55. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy
56. Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial
57. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir
58. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists
59. Neuronal injury associated with HIV-1: Approaches to treatment
60. Dementia associated with the acquired immunodeficiency syndrome
61. A phase I/II trial of nimodipine for HIV-related neurologic complications
62. Randomized, placebo-controlled trial of the PAF antagonist lexipafant in HIV-associated cognitive impairment
63. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment
64. Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study
65. A randomize double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment
66. Phase II trial of CPI-1189 for HIV-associated motor cognitive impairment
67. ACTG 301: A phase II randomized, double-blind, placebo-controlled trial of memantine for AIDS dementia complex (ADC)